In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease. (Biogen via AP)
June 8, 2021
Stories this photo appears in:
June 7, 2021 1:25 p.m.
FDA approves much-debated Alzheimer’s drug panned by experts
decision, which could impact millions of Americans and their families
Decision could impact millions of Americans and their families